Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.
Location: Italy, Piedmont, Turin
Employees: 1-10
Total raised: $28.67M
Founded date: 2021
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.01.2024 | Series A | $10.95M | - |
| 22.02.2023 | Seed | $10.63M | Italian An... |
| 04.08.2021 | Seed | $7.1M | - |
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Alessandro | Toniolo | Chief Exec... | linkedin.c... | - | a*********... | - |
| - | Riccardo | Panella | - | linkedin.c... | - | r*********... | - |
Mentions in press and media 4
| Date | Title | Description |
| 05.01.2024 | Resalis Therapeutics Raises €10M in Series A Funding | Resalis Therapeutics, a Torino, Italy-based ncRNAs and RNA-targeted therapeutics company, raised €10M in Series A funding. The round was led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventu... |
| 04.01.2024 | Torino-based Resalis raises €10 million Series A to provide a therapeutic that reduces fat mass in obesity | - |
| 22.02.2023 | Resalis Therapeutics Raises €10M in Seed Financing | Resalis Therapeutics, a Torino, Italy-based company focused on finding treatments for metabolic diseases, raised €10M in Seed funding. The round was led by Claris Ventures, with participation from Italian Angels for Growth and Club degli In... |
| - | Resalis Therapeutics | “Resalis Therapeutics – Tackling metabolic disorders with non-coding RNAs” |